Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2016-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.6b00544PMID 27275946
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors

  2016cited by this paper
• Novel Fused Arylpyrimidinone Based Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor.

  2016cited by this paper
• Design and optimization of selective azaindole amide M1 positive allosteric modulators.

  2016cited by this paper
• Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model

  2016cited by this paper
• 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor.

  2016cited by this paper
• Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

  2015cited by this paper
• Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors

  2015cited by this paper
• From synthesis to function via iterative assembly of N-methyliminodiacetic acid boronate building blocks.

  2015cited by this paper
• The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys

  2015cited by this paper
• Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos

  2014cited by this paper
• SAR studies on carboxylic acid series M(1) selective positive allosteric modulators (PAMs).

  2014cited by this paper
• Identification of a methoxynaphthalene scaffold as a core replacement in quinolizidinone amide M(1) positive allosteric modulators.

  2014cited by this paper
• Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia

  2014cited by this paper
• Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor*

  2014cited by this paper
• Synthesis and pharmacological evaluation of analogues of benzyl quinolone carboxylic acid (BQCA) designed to bind irreversibly to an allosteric site of the M ₁ muscarinic acetylcholine receptor.

  2014cited by this paper
• Development of a photoactivatable allosteric ligand for the m1 muscarinic acetylcholine receptor.

  2014cited by this paper
• Discovery of naphthyl-fused 5-membered lactams as a new class of m1 positive allosteric modulators.

  2014cited by this paper
• Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor.

  2013cited by this paper
• Activation and allosteric modulation of a muscarinic acetylcholine receptor

  2013cited by this paper
• The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque

  2012cited by this paper
• Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

  2012cited by this paper
• Identification of amides as carboxylic Acid surrogates for quinolizidinone-based m1 positive allosteric modulators.

  2012cited by this paper
• Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series.

  2011cited by this paper
• Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe.

  2011cited by this paper
• Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold.

  2011cited by this paper
• Development of a new permeability assay using low-efflux MDCKII cells.

  2011cited by this paper
• M1 and M4 receptors modulate hippocampal pyramidal neurons.

  2011cited by this paper
• Fused heterocyclic M1 positive allosteric modulators.

  2011cited by this paper
• Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.

  2010cited by this paper
• Quinolizidinone carboxylic acids as CNS penetrant, selective m1 allosteric muscarinic receptor modulators.

  2010cited by this paper
• Iterative Cross-Couplng with MIDA Boronates: Towards a General Platform for Small Molecule Synthesis.

  2010cited by this paper
• N-heterocyclic derived M1 positive allosteric modulators.

  2010cited by this paper
• The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

  2009cited by this paper
• Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.

  2009cited by this paper
• Using the Golden Triangle to optimize clearance and oral absorption.

  2009cited by this paper
• Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation

  2009cited by this paper
• A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning

  2009cited by this paper
• In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System

  2008cited by this paper
• Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats

  2008cited by this paper
• Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview.

  2008cited by this paper
• Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584.

  2008cited by this paper
• Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1

  2008cited by this paper
• The role of blood-brain barrier studies in the pharmaceutical industry.

  2006cited by this paper
• Allosteric Modulation of the Cannabinoid CB1 Receptor

  2005cited by this paper
• New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism

  2005cited by this paper
• Analysis of Allosterism in Functional Assays

  2005cited by this paper
• Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.

  2004cited by this paper
• ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.

  2001cited by this paper
• Anticholinergicity and cognitive processing in chronic schizophrenia.

  2001cited by this paper
• Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication.

  2000cited by this paper
• Therapeutic opportunities for muscarinic receptors in the central nervous system.

  2000cited by this paper
• Muscarinic M1 agonists in the treatment of Alzheimer’s disease

  2000cited by this paper
• A simple method for estimation of agonist activity at receptor subtypes: comparison of native and cloned M3 muscarinic receptors in guinea pig ileum and transfected cells.

  1999cited by this paper
• Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice.

  1997cited by this paper
• Functional role of M2 muscarinic receptors in the guinea pig ileum.

  1995cited by this paper
• Involvement of M1 muscarinic receptors in the initiation of cholinergically induced epileptic seizures in the rat brain.

  1994cited by this paper

• Computational Studies toward the Identification of CB2R-M1R Dual Modulators.

  2026cites this paper
• Automated Iterative N─C and C─C Bond Formation

  2025cites this paper
• Bitopic A3 Adenosine Receptor Molecular Probes: Positive Allosteric Modulation and Noncanonical Activation.

  2025cites this paper
• Discovery of a Novel sp3‑Rich M1 Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping.

  2025cites this paper
• Allosteric modulation of neurotransmission.

  2025cites this paper
• The Prosperity and Adversity of M4 Muscarinic Acetylcholine Receptor Activators in the Treatment of Neuropsychiatric Disorders.

  2025cites this paper
• Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M4 Muscarinic Acetylcholine Receptor.

  2024cites this paper
• A golden age of muscarinic acetylcholine receptor modulation in neurological diseases

  2024cites this paper
• Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.

  2024cites this paper
• Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases

  2023cites this paper
• Acetylcholine receptors (muscarinic) in GtoPdb v.2023.1

  2023cites this paper
• Late-stage Functionalization for Improving Drug-like Molecular Properties.

  2023cites this paper
• Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders

  2022cites this paper
• Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease

  2022cites this paper
• Multitargeting nature of muscarinic orthosteric agonists and antagonists

  2022cites this paper
• M1-selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primates

  2022cites this paper
• Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.

  2022cites this paper
• Recent advances in the synthesis and reactivity of MIDA boronates.

  2022cites this paper
• Opportunities and challenges for the development of M1 muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits

  2022influential citation
• Therapeutic approaches for improving cognitive function in the aging brain

  2022cites this paper
• Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders

  2022cites this paper
• Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.

  2021cites this paper
• Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias

  2021influential citation
• Targeting Muscarinic Receptors to Treat Schizophrenia.

  2021cites this paper
• Discovery of a Novel Class of Heteroaryl-Pyrrolidinones as Positive Allosteric Modulators of the Muscarinic Acetylcholine Receptor M1.

  2021cites this paper
• Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects

  2021cites this paper
• Acetylcholine receptors (muscarinic) in GtoPdb v.2021.3

  2021cites this paper
• From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease

  2021cites this paper
• M1 muscarinic receptor activation decreases alcohol consumption via a reduction in consummatory behavior

  2021cites this paper
• Acetylcholine receptors (muscarinic) in GtoPdb v.2021.2

  2021cites this paper
• M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?

  2020cites this paper
• First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias

  2020cites this paper
• Development of Novel 4-Arylpyridin-2-one and 6-Arylpyrimidin-4-one Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor

  2020cites this paper
• Effects of muscarinic M1 receptor stimulation on reinforcing and neurochemical effects of cocaine in rats

  2020cites this paper
• T‐495, a novel low cooperative M1 receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk

  2020cites this paper
• Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs

  2020cites this paper
• G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

  2020cites this paper
• Biased Receptor Signaling in Drug Discovery

  2019cites this paper
• Acetylcholine receptors (muscarinic) (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Rapid and efficient synthesis of a novel cholinergic muscarinic M1 receptor positive allosteric modulator using flash chemistry.

  2019cites this paper
• Prescient Indices of Activity: The Application of Functional System Sensitivity to Measurement of Drug Effect.

  2019cites this paper
• In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents.

  2019cites this paper
• Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review

  2019cites this paper
• Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs

  2019cites this paper
• Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.

  2019cites this paper
• Regio- and Stereoselective Synthesis of Thiazole-Containing Triarylethylenes by Hydroarylation of Alkynes.

  2019cites this paper
• Die molekulare industrielle Revolution: zur automatisierten Synthese organischer Verbindungen

  2018cites this paper
• Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor

  2018cites this paper
• The Molecular Industrial Revolution: Automated Synthesis of Small Molecules.

  2018cites this paper
• M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition

  2018cites this paper
• Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.

  2018cites this paper
• Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators

  2018cites this paper
• Transforming Benzylic Amines into Diarylmethanes: Cross-Couplings of Benzylic Pyridinium Salts via C-N Bond Activation.

  2018cites this paper
• A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

  2018cites this paper
• Harnessing biosynthesis and quantitative NMR for late stage functionalization of lead molecules: Application to the M1 positive allosteric modulator (PAM) program.

  2018cites this paper
• Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M1 Muscarinic Acetylcholine Receptors

  2018cites this paper
• Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases.

  2018cites this paper
• Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes

  2018cites this paper
• Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor

  2018cites this paper
• MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate.

  2018cites this paper
• Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M1 Positive Allosteric Modulators.

  2018cites this paper
• VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events.

  2018cites this paper
• In Vivo Modulation of Hippocampal Excitability by M4 Muscarinic Acetylcholine Receptor Activator: Implications for Treatment of Alzheimer's Disease and Schizophrenic Patients.

  2018cites this paper
• Peridinin Is an Exceptionally Potent and Membrane-Embedded Inhibitor of Bilayer Lipid Peroxidation.

  2018cites this paper
• Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.

  2018cites this paper
• Leveraging chromatography based physicochemical properties for efficient drug design

  2018cites this paper
• 6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M1 mAChR: The Determinants of Allosteric Activity.

  2018cites this paper
• Toward Generalization of Iterative Small Molecule Synthesis.

  2018cites this paper
• Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles.

  2018cites this paper
• Recent advances in drug discovery of GPCR allosteric modulators for neurodegenerative disorders

  2017cites this paper
• Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.

  2017cites this paper
• Conformational control in structure-based drug design.

  2017cites this paper
• Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.

  2017cites this paper
• Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats

  2017cites this paper
• Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease.

  2017cites this paper
• Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity.

  2017cites this paper
• Discovery of the first low-shift positive allosteric modulators for the muscarinic M1 receptor.

  2017cites this paper
• Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

  2017cites this paper
• Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia

  2017cites this paper
• Inositol Phosphate Accumulation in Vivo Provides a Measure of Muscarinic M1 Receptor Activation.

  2016cites this paper